# FDA Approves Generic Tofacitinib from Novadoz Pharmaceuticals Novadoz Pharmaceuticals LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking a significant entry into the competitive JAK inhibitor market and opening cost-reduction opportunities for patients currently reliant on branded alternatives. The approval is expected to intensify pricing competition in the rheumatoid arthritis and ulcerative colitis segments, potentially reshaping market dynamics as multiple generic competitors vie for formulary placement and volume discounts from payers and healthcare systems.